Back to top anchor

Hypothalamic inhibition of GIPR signalling to increase health during ageing

Year:
2024
Duration:
27 months
Approved budget:
$400,000.00
Researchers:
Dr Geke Aline Boer
,
Dr Michael Garratt
Host:
University of Otago
Health issue:
Ageing
Proposal type:
Emerging Researcher First Grant
Lay summary
The population in New Zealand and worldwide is ageing. Ageing is associated with an increased risk of health problems, including the development of type 2 diabetes, obesity, heart disease, and a decline in memory function. This research will investigate the hormone glucose-dependent insulinotropic polypeptide (GIP) and its potential to influence ageing and ageing-related health problems. We will use a genetically modified mouse model in which, at a mid-stage in life, we can prevent GIP from functioning in a specific region of the brain. We will then determine if inhibiting GIP’s function delays the development of ageing and extends a healthy lifespan. The knowledge acquired by this study could, in the long-term, contribute to the development of GIP-based treatments to improve health during ageing, thereby providing major long-term health benefits for New Zealanders.